-
Natural history of saccadic abnormalities in spinocerebellar ataxia 2: Implications to designing future clinical trials
-
ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump
-
Neck proprioception is impaired in patients with idiopathic cervical dystonia
-
Negative dystonia of the palate: Mutation in the THAP1 (DYT6) gene found in a 42 years old patient
-
Negative emotional signals impair isometric force control in Parkinson’s disease
-
Neural mechanisms underlying step initiation failure in patients with Parkinson’s disease and freezing of gait
-
Neural plasticity and freezing of gait: Stepping through the FoG
-
Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson’s disease: A resting state functional MRI study
-
Neuro-cognitive domain related to conversion of Parkinson’s disease dementia
-
Neuroanatomical correlates of apathy in non-demented and non-depressed Parkinson’s disease
-
Neurocognitive domains of impulsivity in Parkinson’s disease (PD) and the effects of dopaminergic replacement therapy (DRT)
-
Neurodegeneration and microgliosis are independent of α-synuclein aggregation in a mouse model of "prion-like" α-synuclein speading
-
Neurodegeneration with brain iron accumulation (NBIA): Two cases with different subtypes and a rare mutation
-
Neurodegenerative disorders with atypical course and cause, diagnostic contribution of genetics and magnetic resonance imaging, two case reports
-
Neuroleptic medication is associated with a worse health status in the years prior to treatment, but have the potential for normalization
-
Neurologic phenotipic variability in spinocerebelar ataxia hype 2 (SCA2)
-
Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2
-
Neuromelanin in Parkinson’s disease: A 3 T MRI study
-
Neuromelanin-MRI of substantia nigra subregions in Parkinson’s disease
-
Neuron specific protein S100B and cognitive impairment in various forms parkinsonism
-
Neuronal nicotinamide-N-methyltransferase (NNMT) in Parkinson’s disease
-
Neurophysiological assessment of corticospinal tract activation due to subthalamic deep brain stimulation in patients with Parkinson’s disease
-
Neurophysiological evidence of posterior-cortical alterations in premanifest Huntington’s: An event-related brain potentials study of face and face-like objects processing
-
Neurophysiological investigation of brainstem in idiopathic REM sleep behavior disorder (iRBD) through vestibular evoked myogenic potentials (VEMPs)
-
Neuroprotection effect of an endogenous amine, 1MeTIQ against disturbances in dopamine release induced by the neurotoxin, 6-OHDA: In vivo microdialysis study
-
Neuroprotective and antidepressant-like effects of the endogenous amines from tetrahydroisoquinoline group TIQ and 1MeTIQ in the animal model of depressive disorder: Behavioral and neurochemical studies in the rat
-
Neuroprotective potential of L-theanine against excitotoxic neuronal death induced by quinolinic acid: Possible neurotransmitters and nitric oxide modulation mechanism
-
Neuropsychiatric disturbances in Parkinson’s disease patients’ with chronic pain
-
Neuropsychiatric, personality and non-motor correlates of impulse control disorders in recent onset Parkinson’s disease
-
Neuropsychological assessment in a cohort of patients with Parkinson’s disease
-
Neuropsychological assessment in the Luxembourg Parkinson’s cohort (HELP-PD)
-
Neuropsychological correlates of impulse control disorders and punding in Parkinson´ s disease
-
Neuropsychological safety of bilateral pallidal (GPi) deep brain stimulation (DBS) for Parkinson’s disease (PD) under general anesthesia
-
Neuropsychological subgroups in non-demented Parkinson’s disease: A latent class analysis
-
Neuropsychology and magnetic resonance correlation in Parkinson´s disease mild cognitive impairment: Case-control study
-
New therapeutic algorithm for abnormal posture in Parkinson’s disease and related disorders
-
Next-generation profiling to identify the molecular etiology of Parkinson’s disease dementia
-
Nighttime sleep problems in patients with Parkinson’s disease: Risk factors and longitudinal associations
-
Nigrostriatal degeneration and serum BDNF levels in patients with “de novo” untreated Parkinson’s disease
-
Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
-
Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
-
Ninjurin 1 gene D110a single nucleotide polymorphism as a genetic marker for nerve damage leprosy patients from South India
-
No RAB39B gene mutations in Chinese familial Parkinson’s disease
-
Non motor symptoms burden and motor staging of Parkinson’s disease: Evidence for dichotomy and non-motor dominant subtypes from analysis of 249 cases
-
Non motor symptoms of Parkinson’s disease: Prevalence and impact on quality of life
-
Non-contact boxing in Parkinson’s disease
-
Non-motor outcomes of subthalamic stimulation in Parkinson’s disease depend on the location of active contacts
-
Non-motor symptoms (NMS) as a determinant of caregiver burden in a cohort of older patients with Parkinson’s disease (PD)
-
Non-motor symptoms evaluation in idiopathic cervical dystonia
-
Non-motor symptoms in a PPMI cohort of p.A53T α-synuclein mutation-related and sporadic Parkinson’s disease patients
-
Non-motor symptoms in advanced Parkinson’s disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis
-
Non-motor symptoms in PD candidates for DBS treatment
-
Non-motor symptoms in progressive supranuclear palsy
-
Non-motor symptoms profiles in UK white Caucasian and Asian as well as overseas Thai and East Indian patients with Parkinson’s disease
-
Non-motor symptoms trajectory in Parkinson’s disease: Magnitude and importance of the change
-
Novel PLA2G6 c.1627C>T homozygous mutation and response to DBS-GPi
-
Novel mutations identified in dopamine transporter deficiency syndrome
-
Novel PET Tracers of alpha-synuclein for the diagnosis of Parkinson’s disease
-
Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
-
Novel THAP1 missense mutation leading to focal and segmental dystonia
-
Novel training based on declarative memory cues improves gait perfromance in patients with Parkinson’s disease: A randomized clinical trial
-
Novel variants in the SACS gene in a first Central-Eastern European family with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)
-
NREM parasomnias as a marker of cognitive impairment in Parkinson’s disease
-
Nursing diagnoses and interventions in rehabilitation related to antiParkinsonian pharmacotherapy
-
Nutritional status and quality of life in patients with Parkinson’s disease in a tertiary hospital in Northeast Mexico
-
Nystagmus in essential tremor
-
Nystagmus in harmaline induced tremors in rats and attenuation with ethanol
2016 International Congress
June 19-23, 2016. Berlin, Germany.